Form 144 discloses director Merline Saintil's intent to sell 12,706 shares of Rocket Lab USA Inc. (RKLB) common stock under Rule 144. Shares were acquired on June 12, 2025, through vesting of restricted stock units directly from the issuer, with no payment required beyond service. The proposed sale to Morgan Stanley broker has an aggregate market value of $353,862.10 based on current pricing, against 461,432,393 shares outstanding. No securities sold by Saintil in the prior 3 months. The filing relies on a Rule 10b5-1 trading plan adopted March 20, 2025, providing safe harbor against insider trading allegations. Saintil certifies no undisclosed material adverse information. This is a standard disclosure for affiliate sales of restricted securities post-vesting, common for directors fulfilling compensation via equity.

Minimal impact for RKLB investors; 12,706 shares represent negligible dilution (<0.003%) and routine RSU vesting monetization by director. Pre-planned 10b5-1 sale signals no opportunistic timing amid positive certification of no adverse info. Monitor future insider activity for trends, but this isolated event unlikely to affect stock or operations.